KR102727229B1 - Cd73 억제제 - Google Patents

Cd73 억제제 Download PDF

Info

Publication number
KR102727229B1
KR102727229B1 KR1020247010203A KR20247010203A KR102727229B1 KR 102727229 B1 KR102727229 B1 KR 102727229B1 KR 1020247010203 A KR1020247010203 A KR 1020247010203A KR 20247010203 A KR20247010203 A KR 20247010203A KR 102727229 B1 KR102727229 B1 KR 102727229B1
Authority
KR
South Korea
Prior art keywords
alkyl
cycloalkyl
heterocycloalkyl
heteroaryl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020247010203A
Other languages
English (en)
Korean (ko)
Other versions
KR20240042573A (ko
Inventor
시아오후이 두
존 엑스터오비츠
발레리아 알 팬틴
다칭 순
치우핑 예
자레드 무어
타티아나 자보로틴스카야
브라이언 알 블랑크
요섭 레우
케지아 우
리우셩 주
조니 팜
히로유키 가와이
치엔-훙 예
Original Assignee
오릭 파마슈티칼스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오릭 파마슈티칼스, 인크. filed Critical 오릭 파마슈티칼스, 인크.
Publication of KR20240042573A publication Critical patent/KR20240042573A/ko
Application granted granted Critical
Publication of KR102727229B1 publication Critical patent/KR102727229B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020247010203A 2019-10-30 2020-10-29 Cd73 억제제 Active KR102727229B1 (ko)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201962928138P 2019-10-30 2019-10-30
US62/928,138 2019-10-30
US202062987806P 2020-03-10 2020-03-10
US62/987,806 2020-03-10
US202063088646P 2020-10-07 2020-10-07
US63/088,646 2020-10-07
PCT/US2020/057996 WO2021087136A1 (en) 2019-10-30 2020-10-29 Cd73 inhibitors
KR1020227018155A KR102653726B1 (ko) 2019-10-30 2020-10-29 Cd73 억제제

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020227018155A Division KR102653726B1 (ko) 2019-10-30 2020-10-29 Cd73 억제제

Publications (2)

Publication Number Publication Date
KR20240042573A KR20240042573A (ko) 2024-04-02
KR102727229B1 true KR102727229B1 (ko) 2024-11-06

Family

ID=75686256

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020247010203A Active KR102727229B1 (ko) 2019-10-30 2020-10-29 Cd73 억제제
KR1020227018155A Active KR102653726B1 (ko) 2019-10-30 2020-10-29 Cd73 억제제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020227018155A Active KR102653726B1 (ko) 2019-10-30 2020-10-29 Cd73 억제제

Country Status (19)

Country Link
US (7) US12577272B2 (cg-RX-API-DMAC7.html)
EP (2) EP4051688B1 (cg-RX-API-DMAC7.html)
JP (2) JP7544815B2 (cg-RX-API-DMAC7.html)
KR (2) KR102727229B1 (cg-RX-API-DMAC7.html)
CN (2) CN116854758A (cg-RX-API-DMAC7.html)
AU (1) AU2020375914B2 (cg-RX-API-DMAC7.html)
CA (1) CA3159248C (cg-RX-API-DMAC7.html)
DK (1) DK4051688T3 (cg-RX-API-DMAC7.html)
ES (1) ES3034168T3 (cg-RX-API-DMAC7.html)
FI (1) FI4051688T3 (cg-RX-API-DMAC7.html)
HU (1) HUE072504T2 (cg-RX-API-DMAC7.html)
IL (2) IL292570B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022005256A (cg-RX-API-DMAC7.html)
PL (1) PL4051688T3 (cg-RX-API-DMAC7.html)
PT (1) PT4051688T (cg-RX-API-DMAC7.html)
SI (1) SI4051688T1 (cg-RX-API-DMAC7.html)
TW (1) TWI830962B (cg-RX-API-DMAC7.html)
WO (1) WO2021087136A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202204941B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11129841B2 (en) 2017-05-10 2021-09-28 Oric Pharmaceuticals, Inc. CD73 inhibitors
US11377469B2 (en) 2017-11-03 2022-07-05 Oric Pharmaceuticals, Inc. CD73 inhibitors
CA3098493A1 (en) 2018-04-30 2019-11-07 Oric Pharmaceuticals, Inc. Cd73 inhibitors
US12544391B2 (en) 2019-07-16 2026-02-10 Oric Pharmaceuticals, Inc. CD73 inhibitors
CN116854758A (zh) 2019-10-30 2023-10-10 欧瑞克制药公司 Cd73抑制剂
AU2023252914A1 (en) 2022-04-13 2024-10-17 Arcus Biosciences, Inc. Combination therapy for treating trop-2 expressing cancers
CA3266927A1 (en) * 2022-09-14 2024-03-21 Oric Pharmaceuticals, Inc. PHARMACEUTICAL FORMS OF A CD73 INHIBITOR
US20240140980A1 (en) * 2022-10-03 2024-05-02 Teon Therapeutics, Inc. Heterocyclic inhibitors of cd73 for treatment of disease
US20240140979A1 (en) * 2022-10-03 2024-05-02 Teon Therapeutics, Inc. Heterocyclic inhibitors of cd73 for treatment of disease
WO2025111247A1 (en) * 2023-11-20 2025-05-30 Oric Pharmaceuticals, Inc. Treatment of refractory multiple myeloma
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025233264A1 (en) 2024-05-07 2025-11-13 Innate Pharma Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018208980A1 (en) 2017-05-10 2018-11-15 Oric Pharmaceuticals, Inc. Cd73 inhibitors
WO2019090111A1 (en) 2017-11-03 2019-05-09 Oric Pharmaceuticals, Inc. Cd73 inhibitors

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1023991A (en) 1911-07-29 1912-04-23 Firm B Byers Anti-rail-creeper and splice-bar.
EP0477454A1 (en) 1990-09-28 1992-04-01 Merrell Dow Pharmaceuticals Inc. Novel phosphonate derivatives of certain nucleosides
JP2005502580A (ja) 2000-12-15 2005-01-27 フアーマセツト・リミテツド フラビウィルス感染治療用抗ウィルス薬
US20040229839A1 (en) 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
WO2007139946A2 (en) 2006-05-25 2007-12-06 University Of Tennessee Research Foundation Gpcr ligands identified by computational modeling
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
WO2009127230A1 (en) 2008-04-16 2009-10-22 Curevac Gmbh MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
US20090274686A1 (en) 2008-05-02 2009-11-05 Yat Sun Or Nucleoside phosphonate derivatives
EP3134411B1 (en) * 2014-04-25 2021-06-30 Boehringer Ingelheim International GmbH Purine derivatives as cd73 inhibitors for the treatment of cancer
CN104530166B (zh) 2014-12-04 2016-08-24 陕西汉江药业集团股份有限公司 选择性还原4,6-共轭双烯-3-酮甾体化合物的方法
US10383929B2 (en) * 2014-12-12 2019-08-20 Bluebird Bio, Inc. BCMA chimeric antigen receptors
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
LT3399984T (lt) * 2016-01-08 2023-11-10 Arcus Biosciences, Inc. 5'-nukleotidazės, ekto moduliatoriai ir jų panaudojimas
CN110234656B (zh) 2016-09-09 2023-02-28 卡利泰拉生物科技公司 外核苷酸酶抑制剂及其使用方法
WO2018067424A1 (en) * 2016-10-03 2018-04-12 Arcus Biosciences, Inc. Inhibitors of adenosine 5'-nucleotidase
CN110022881B (zh) 2016-11-18 2023-05-02 艾库斯生物科学有限公司 Cd73介导的免疫抑制的抑制剂
KR102638592B1 (ko) 2016-12-22 2024-02-19 안텐진 테라퓨틱스 리미티드 엑토뉴클레오티다제 억제제 및 이의 용도
WO2018183635A1 (en) * 2017-03-31 2018-10-04 Peloton Therapeutics, Inc. Cd73 inhibitors and uses thereof
WO2018208727A1 (en) * 2017-05-08 2018-11-15 Eternity Bioscience Inc. Nucleoside and nucleotide analogues as cd73 inhibitors and therapeutic uses thereof
CN111094317B (zh) 2017-12-29 2023-03-31 上海和誉生物医药科技有限公司 一种具有cd73抑制活性的膦酸衍生物、其制备方法和应用
CA3098493A1 (en) 2018-04-30 2019-11-07 Oric Pharmaceuticals, Inc. Cd73 inhibitors
TW202017569A (zh) 2018-05-31 2020-05-16 美商佩樂敦治療公司 用於抑制cd73之組合物及方法
KR102902754B1 (ko) 2018-06-21 2025-12-19 안텐진 테라퓨틱스 리미티드 엑토뉴클레오티다제 저해제 및 이의 사용 방법
ES3053198T3 (en) 2018-08-27 2026-01-20 Arcus Biosciences Inc Cd73 inhibitors
CA3143496A1 (en) 2019-06-20 2020-12-24 Antengene Therapeutics Limited Ectonucleotidase inhibitors and methods of use thereof
US12544391B2 (en) 2019-07-16 2026-02-10 Oric Pharmaceuticals, Inc. CD73 inhibitors
CN116854758A (zh) 2019-10-30 2023-10-10 欧瑞克制药公司 Cd73抑制剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018208980A1 (en) 2017-05-10 2018-11-15 Oric Pharmaceuticals, Inc. Cd73 inhibitors
WO2019090111A1 (en) 2017-11-03 2019-05-09 Oric Pharmaceuticals, Inc. Cd73 inhibitors

Also Published As

Publication number Publication date
CN114929721B (zh) 2023-07-18
IL292570B1 (en) 2023-12-01
US11530236B2 (en) 2022-12-20
IL308293B2 (en) 2025-12-01
EP4596048A3 (en) 2025-11-19
ES3034168T3 (en) 2025-08-13
JP7688769B2 (ja) 2025-06-04
CN114929721A (zh) 2022-08-19
JP2024164093A (ja) 2024-11-26
IL292570A (en) 2022-06-01
JP2023500483A (ja) 2023-01-06
US20210214387A1 (en) 2021-07-15
US12454544B2 (en) 2025-10-28
AU2020375914B2 (en) 2024-05-23
TW202130353A (zh) 2021-08-16
FI4051688T3 (fi) 2025-06-27
EP4051688A4 (en) 2024-03-06
EP4051688B1 (en) 2025-04-23
US20250034198A1 (en) 2025-01-30
PL4051688T3 (pl) 2025-09-22
JP7544815B2 (ja) 2024-09-03
EP4596048A2 (en) 2025-08-06
HUE072504T2 (hu) 2025-11-28
US11028120B2 (en) 2021-06-08
CA3159248C (en) 2024-05-28
KR20220088786A (ko) 2022-06-28
US20230131747A1 (en) 2023-04-27
US20210130390A1 (en) 2021-05-06
WO2021087136A1 (en) 2021-05-06
TWI830962B (zh) 2024-02-01
IL308293A (en) 2024-01-01
IL308293B1 (en) 2025-08-01
US12577272B2 (en) 2026-03-17
US20260042794A1 (en) 2026-02-12
US20220411459A1 (en) 2022-12-29
AU2020375914A1 (en) 2022-06-02
US20210130389A1 (en) 2021-05-06
BR112022008365A2 (pt) 2023-03-28
IL292570B2 (en) 2024-04-01
SI4051688T1 (sl) 2025-08-29
MX2022005256A (es) 2022-08-25
CA3159248A1 (en) 2021-05-06
EP4051688A1 (en) 2022-09-07
ZA202204941B (en) 2024-10-30
US11130778B2 (en) 2021-09-28
US12018043B2 (en) 2024-06-25
KR102653726B1 (ko) 2024-04-01
BR122023021184A2 (pt) 2024-02-27
NZ788133A (en) 2024-03-22
DK4051688T3 (da) 2025-06-30
KR20240042573A (ko) 2024-04-02
CN116854758A (zh) 2023-10-10
PT4051688T (pt) 2025-06-30

Similar Documents

Publication Publication Date Title
KR102653726B1 (ko) Cd73 억제제
US11807658B2 (en) CD73 inhibitors
BR112022008365B1 (pt) Compostos inibidores de cd73, composição farmacêutica que oscompreende, método de inibição de cd73 in vitro e uso dos referidos compostos
BR122023021184B1 (pt) Compostos inibidores de cd73, composição farmacêutica que os compreende, método de inibição de cd73 in vitro e uso dos referidos compostos
HK40081385B (en) Cd73 inhibitors
HK40081385A (en) Cd73 inhibitors
EA046660B1 (ru) Ингибиторы cd73

Legal Events

Date Code Title Description
PA0104 Divisional application for international application
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240422

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20241024

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20241104

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20241104

End annual number: 3

Start annual number: 1

PG1601 Publication of registration